PPIDT00080
Drug Information
| Name | Filgrastim |
|---|---|
| Sequence | MTPLGPASSLPQSFLLKCLEQVRKIQGDGAALQEKLCATYKLCHPEELVLLGHSLGIPWAPLSSCPSQALQLAGCLSQLHSGLFLYQGLLQALEGISPELGPTLDTLQLDVADFATTIWQQMEELGMAPALQPTQGAMPAFASAFQRRAGGVLVASHLQSFLEVSYRVLRHLAQP |
| DrugBank_ID | DB00099 |
| Type | biotech |
| Indication | Filgrastim is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever.[L40714] Filgrastim is indicated for reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia.[L40714] Filgrastim is indicated to reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ e.g.‚ febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation.[L40714] Filgrastim is indicated for the mobilization of autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis.[L40714] Filgrastim is indicated for chronic administration to reduce the incidence and duration of sequelae of neutropenia (e.g.‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia.[L40714] Filgrastim is indicated to increase survival in patients acutely exposed to myelosuppressive doses of radiation.[L40714] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, solution | Intravenous; Subcutaneous |
12000000 U/0.2ml
|
| Injection, solution | Intravenous; Subcutaneous |
30000000 U/0.5ml
|
| Injection, solution | Intravenous; Subcutaneous |
48000000 U/0.5ml
|
| Injection, solution | Intravenous; Subcutaneous |
70000000 U/0.73ml
|
| Injection, solution | Parenteral; Subcutaneous |
12 MU/0.2ml
|
| Injection, solution | Parenteral; Subcutaneous |
70 MU/0.73ml
|
| Injection | Parenteral |
30 MIO.E./0.5ML
|
| Injection | Parenteral |
0.5 ML
|
| Injection, solution | Intravenous; Subcutaneous |
300 mcg/0.5mL
|
| Injection | Parenteral |
30 MIO E/0.5ML
|
| Injection | Parenteral |
48 MIO.E./0.5ML
|
| Injection, solution | Intravenous; Subcutaneous |
480 mcg/0.5mL
|
| Injection | Parenteral |
48 MIO E/0.5ML
|
| Solution | Intravenous; Subcutaneous |
48000000 mcg
|
| Solution | Parenteral |
300.0 mcg
|
| Injection, solution | Intravenous; Subcutaneous |
30 MIU
|
| Injection, solution | Intravenous; Subcutaneous |
48 MIU
|
| Solution | Subcutaneous |
300.000 mg
|
| Solution | Intravenous; Subcutaneous |
30000000 mcg
|
| Injection, solution | Intravenous; Subcutaneous |
60 MU/ml
|
| Injection, solution | Intravenous; Subcutaneous |
96 MU/ml
|
| Injection | Parenteral |
0.3 mg
|
| Injection | Parenteral |
0.48 mg
|
| Injection | Intravenous |
|
| Injection | Intravenous |
30 miu/0.5ml
|
| Injection | Intravenous |
48 miu/0.5ml
|
| Solution | — |
300 mcg/1ml
|
| Injection, solution | Subcutaneous |
300 ug/1mL
|
| Injection, solution | Subcutaneous |
480 ug/1.6mL
|
| Injection, solution, concentrate | Intravenous; Subcutaneous |
30 MU/ml
|
| Injection, solution, concentrate | Subcutaneous |
300 mcg
|
| Injection, solution, concentrate | Subcutaneous |
480 mcg
|
| Solution | Subcutaneous |
300.00 mcg
|
| Injection, solution | Subcutaneous |
48 MU/0.5ml
|
| Solution | Intravenous; Subcutaneous |
300 mcg / 0.5 mL
|
| Solution | Intravenous; Subcutaneous |
480 mcg / 0.8 mL
|
| Solution | Parenteral |
300 mcg
|
| Solution | Subcutaneous |
30000000 mcg
|
| Solution | Subcutaneous |
48000000 mcg
|
| Solution | Parenteral |
300.000 mcg
|
| Injection; injection, solution | — |
300 MCG/ML
|
| Injection | Intravenous; Subcutaneous |
15 miu
|
| Injection | Intravenous; Subcutaneous |
|
| Injection | Intravenous; Subcutaneous |
30 miu
|
| Injection, solution | — |
480 mcg/ml
|
| Injection | Intravenous; Subcutaneous |
30 miu/ml
|
| Injection | — |
300 mcg/ml
|
| Solution | Subcutaneous |
300.00 ug
|
| Injection, solution | — |
30 MU
|
| Injection, solution | — |
48 MU
|
| Injection, solution | Intravenous |
300 ug/0.5mL
|
| Injection, solution | Intravenous |
300 ug/1mL
|
| Injection, solution | Intravenous |
480 ug/0.8mL
|
| Solution | Intravenous; Subcutaneous |
300 mcg / mL
|
| Solution | Intravenous; Subcutaneous |
600 mcg / mL
|
| Solution | Subcutaneous |
0.300 mg
|
| Injection, solution | Intravenous; Subcutaneous |
0.3 MG/ML
|
| Injection | Parenteral |
300 ug/0.5ml
|
| Injection | Parenteral |
30 MIO.E.
|
| Injection | Parenteral |
300 UG/1ML
|
| Injection | Parenteral |
480 ug/0.5ml
|
| Injection | Parenteral |
48 MIO.E.
|
| Injection | Parenteral |
480 UG
|
| Injection | Parenteral |
480 UG/0.5ML
|
| Injection | Intravenous; Subcutaneous |
300 mcg/ml
|
| Injection | Intravenous; Subcutaneous |
480 mcg/1.6ml
|
| Injection | Intravenous; Subcutaneous |
30 mu/0.5ml
|
| Injection | Intravenous; Subcutaneous |
48 mu/0.5ml
|
| Injection, solution | Intravenous; Subcutaneous |
30 MU/0.5ML
|
| Injection; solution | Intravenous; Subcutaneous |
30 miu/0.5ml
|
| Injection; solution | Intravenous; Subcutaneous |
48 miu/0.5ml
|
| Solution | Intravenous; Subcutaneous |
30 millions of units
|
| Injection, solution | — |
480 mcg/1vial
|
| Injection, solution | Intravenous; Subcutaneous |
12 MU/0.2ml
|
| Injection, solution | Intravenous; Subcutaneous |
12000000 [units of filgrastim]/0.2mL
|
| Injection, solution | Intravenous; Subcutaneous |
30000000 [units of filgrastim]/0.5mL
|
| Injection, solution | Intravenous; Subcutaneous |
48 MU/0.5ml
|
| Injection, solution | Intravenous; Subcutaneous |
48000000 [units of filgrastim]/0.5mL
|
| Injection | Parenteral |
12 MIO E/0.2ML
|
| Injection | Parenteral |
0.2 ML
|
| Injection, solution | Intravenous; Subcutaneous |
120 mcg/0.2ml
|
| Injection, solution | Intravenous drip; Subcutaneous |
0.120 mg/0.2ml
|
| Injection, solution | Intravenous |
|
| Solution | Intravenous drip; Subcutaneous |
0.300 mg/0.5ml
|
| Injection | Parenteral |
05 ML
|
| Solution | Intravenous drip; Subcutaneous |
0.480 mg/0.5ml
|
| Injection, solution | — |
120 mcg/0.2ml
|
| Injection, solution | Intravenous; Subcutaneous |
300 ug/1mL
|
| Injection, solution | Intravenous; Subcutaneous |
480 ug/1.6mL
|
| Injection, solution | Subcutaneous |
300 ug/0.5mL
|
| Injection, solution | Subcutaneous |
480 ug/0.8mL
|
| Solution | Intravenous; Subcutaneous |
480 mcg / 1.6 mL
|
| Solution | Intravenous; Subcutaneous |
300 cg
|
| Injection | Subcutaneous |
300 ug/300ug
|
| Injection | Subcutaneous |
480 ug/480ug
|
| Injection, solution | Intravenous; Subcutaneous |
30 MIU/0.5ml
|
| Injection, solution | Intravenous; Subcutaneous |
48 MIU/0.8ml
|
| Injection | Parenteral |
30 M UI/0.5 ml
|
| Injection | Parenteral |
48 M UI/0.8 ml
|
| Injection | Parenteral |
0.8 ML
|
| Injection, solution | Intravenous; Subcutaneous |
30 MUI/0.5ml
|
| Injection, solution | Intravenous; Subcutaneous |
300 ug/0.5 ml
|
| Injection, solution | Intravenous; Subcutaneous |
48 MUI/0.8ml
|
| Injection, solution | Intravenous; Subcutaneous |
480 ug/0.8 ml
|
| Injection, solution | Intravenous; Subcutaneous |
300 ug/0.5mL
|
| Injection, solution | Intravenous; Subcutaneous |
480 ug/0.8mL
|
| Solution | Subcutaneous |
300.000 mcg
|
| Injection, solution | — |
480 mcg/1ml
|
| Injection | Parenteral |
30 MIO E./0.5ML
|
| Solution | Intravenous; Subcutaneous |
300 mcg/0.5ml
|
| Injection | Parenteral |
48 MIO E./0.5ML
|
| Solution | Intravenous; Subcutaneous |
480 mcg/0.5ml
|
| Injection, solution | Intravenous; Subcutaneous |
0.3 mg/0.5ml
|
| Solution | Intravenous; Subcutaneous |
3000000 million IU
|
| Injection, solution | — |
10000 iu/10ml
|
| Injection, solution | — |
300 mcg/0.5ml
|
| Injection, solution | — |
480 mcg/0.5ml
|
| Solution | — |
300 mcg/1vial
|
| Solution | — |
480 mcg/1vial
|
| Injection, solution | — |
300 mcg/1ml
|
| Injection, solution | — |
300 mcg/ml
|